14.45
+0.2(+1.40%)
Currency In USD
Address
320 West 37th Street
New York, NY 10018
United States of America
Phone
917 580 3099
Website
Sector
Healthcare
Industry
Biotechnology
Employees
207
First IPO Date
June 21, 2019
| Name | Title | Pay | Year Born |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 92,500 | 1979 |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer | 683,490 | 1963 |
| Ms. Lauren Schrier M.B.A. | Vice President of Marketing | 0 | N/A |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary | 0 | 1976 |
| Ms. Christine Blodgett | Senior Vice President of Human Resources | 0 | N/A |
| Mr. Andy Deig | Senior Vice President of Strategic Finance | 0 | N/A |
| Ms. Julie Kirschling | Senior Vice President of Program & Alliance Management | 0 | N/A |
| Ms. Jody Roth M.S., P.M.P. | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Dr. Michael Geffner M.B.A., M.D., Ph.D. | Chief Medical Officer | 0 | 1969 |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer | 0 | 1979 |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.